(Q24187413)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25486075%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

1 reference

title

Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25486075%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

chronic renal insufficiency

1 reference

1

Suetonia C Palmer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25486075%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

2

Valeria Saglimbene

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25486075%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Georgia Salanti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25486075%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Jonathan Craig

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25486075%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Natasha Wiebe

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25486075%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

8

Giovanni F M Strippoli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25486075%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

6

Marcello Tonelli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25486075%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Dimitris Mavridis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25486075%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

English

0 references

publication date

8 December 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25486075%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25486075%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25486075%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

CD010590

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25486075%20AND%20SRC:MED&resulttype=core&format=json

Effect of anemia correction on left ventricular hypertrophy in patients with modestly high hemoglobin level and chronic kidney disease .

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Association of anemia correction with health related quality of life in patients not on dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Dialysis patients treated with Epoetin α show improved exercise tolerance and physical function: A new analysis of the Canadian Erythropoietin Study Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Atherosclerotic renal artery stenosis is prevalent in cardiorenal patients but not associated with left ventricular function and myocardial fibrosis as assessed by cardiac magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Determinants of red cell distribution width (RDW) in cardiorenal patients: RDW is not related to erythropoietin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Short- and long-term effects of erythropoietin treatment on endothelial progenitor cell levels in patients with cardiorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Short-term erythropoietin treatment does not substantially modulate monocyte transcriptomes of patients with combined heart and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Epoetin delta in the management of renal anaemia: results of a 6-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Anaemia in diabetes: Is there a rationale to TREAT?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Evaluation of hemodialysis patients treated with erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

New strategies in anaemia management: ACORD (Anaemia CORrection in Diabetes) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

The normal hematocrit cardiac trial revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Randomized trial of model predictive control for improved anemia management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Correction of postkidney transplant anemia reduces progression of allograft nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: effect of long-term therapy with erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

The use of pretransplant erythropoietin to normalize hemoglobin levels has no deleterious effects on renal transplantation outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non-anemic patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Comparative effectiveness studies to improve clinical outcomes in end stage renal disease: the DEcIDE patient outcomes in end stage renal disease study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Graphical tools for network meta-analysis in STATA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

GRADE guidelines: 3. Rating the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Anemia and mortality in heart failure patients a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Combination of direct and indirect evidence in mixed treatment comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Novel erythropoiesis-stimulating agents: a new era in anemia management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Hemoglobin may contribute to sex differences in mortality among HIV-infected persons in care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Darbepoetin for the anaemia of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Evaluation of networks of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Evaluating the quality of evidence from a network meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

The impact of anemia on energy and physical functioning in individuals with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretrovial therapy era: relationships with gender

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Erythropoiesis stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Canadian Randomized Trial of Hemoglobin Maintenance to Prevent or Delay Left Ventricular Mass Growth in Patients With CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

An Ongoing Study of Anemia Correction in Chronic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

Effectiveness of treating the renal anemia in chronic hemodialyzed patients by epoietin alpha and beta

21 January 2018

1 reference

12 December 2020

Adverse events of subcutaneous recombinant human erythropoietin therapy

1 reference

12 December 2020

Comparison of intraperitoneal and subcutaneous epoetin alfa in peritoneal dialysis patients

1 reference

12 December 2020

Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Canadian Erythropoietin Study Group

1 reference

12 December 2020

Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study

1 reference

12 December 2020

Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis

1 reference

12 December 2020

An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting

1 reference

12 December 2020

Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia

1 reference

12 December 2020

The normal hematocrit study--follow-up

1 reference

12 December 2020

Erythropoietin treatment in patients with combined heart and renal failure: objectives and design of the EPOCARES study.

1 reference

12 December 2020

1 reference

12 December 2020

Effect of early correction of anemia on the progression of CKD

1 reference

12 December 2020

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

12 December 2020

Reduced hemodialysis adequacy after hemoglobin normalization with epoetin

1 reference

12 December 2020

Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study

1 reference

12 December 2020

A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease.

1 reference

12 December 2020

Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis

1 reference

12 December 2020

Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group)

1 reference

12 December 2020

Once-monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial

1 reference

12 December 2020

Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients

1 reference

12 December 2020

Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease

1 reference

12 December 2020

Adverse events of subcutaneous recombinant human erythropoietin therapy: results of a controlled multicenter European study

1 reference

12 December 2020

Once-Monthly Subcutaneous C.E.R.A. Maintains Stable Hemoglobin Control in Patients with Chronic Kidney Disease on Dialysis and Converted Directly from Epoetin One to Three Times Weekly

1 reference

12 December 2020

Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study

1 reference

12 December 2020

The first human cell line-derived erythropoietin, epoetin-delta (Dynepo), in the management of anemia in patients with chronic kidney disease

1 reference

12 December 2020

Hemorheological and hemodynamic changes in predialysis patients after normalization of hemoglobin with epoetin-alpha

1 reference

12 December 2020

Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review

1 reference

12 December 2020

Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients

1 reference

12 December 2020

Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients

1 reference

12 December 2020

Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment

1 reference

12 December 2020

Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease

1 reference

12 December 2020

Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. The Canadian Erythropoietin Study Group

1 reference

12 December 2020

Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study

1 reference

12 December 2020

Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial

1 reference

12 December 2020

Multicenter trial of erythropoietin in patients on peritoneal dialysis

1 reference

12 December 2020

The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group

1 reference

12 December 2020

The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial

1 reference

12 December 2020

Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease

1 reference

12 December 2020

Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study

1 reference

12 December 2020

Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group

1 reference

12 December 2020

The CREATE trial--building the evidence

1 reference

12 December 2020

Efficacy of Intravenous Methoxy Polyethylene Glycol-Epoetin Beta Administered Every 2 Weeks Compared With Epoetin Administered 3 Times Weekly in Patients Treated by Hemodialysis or Peritoneal Dialysis: A Randomized Trial

1 reference

12 December 2020

Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta

1 reference

12 December 2020

A randomized double-blind study of recombinant human erythropoietin in anaemic hemodialysis patients. Canadian Erythropoietin Study Group.

1 reference

12 December 2020

[The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi-center trial]

1 reference

12 December 2020

CREATE: new strategies for early anaemia management in renal insufficiency.

1 reference

12 December 2020

Dosing darbepoetin alfa

1 reference

12 December 2020

Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis

1 reference

12 December 2020

Anemia and cardiovascular risk: the lesson of the CREATE Trial

1 reference

12 December 2020

A comparison of androgens for anemia in patients on hemodialysis

1 reference

12 December 2020

Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance

1 reference

12 December 2020

Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. The Canadian Erythropoietin Study Group

1 reference

12 December 2020

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

12 December 2020

Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients

1 reference

12 December 2020

Normalization of hematocrit in hemodialysis patients does not affect silent ischemia

1 reference

12 December 2020

Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia

1 reference

12 December 2020

Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease

1 reference

12 December 2020

Hemorheology and fistula function in home hemodialysis patients following erythropoietin treatment: a prospective placebo-controlled study

1 reference

12 December 2020

Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure

1 reference

12 December 2020

Epoetin delta is effective for the management of anaemia associated with chronic kidney disease

1 reference

12 December 2020

Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients

1 reference

12 December 2020

PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin

1 reference

12 December 2020

C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study

1 reference

12 December 2020

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target

1 reference

12 December 2020

Treatment of the anemia of progressive renal failure with recombinant human erythropoietin

1 reference

12 December 2020

Neutrophil gelatinase-associated lipocalin (NGAL) in chronic cardiorenal failure is correlated with endogenous erythropoietin levels and decreases in response to low-dose erythropoietin treatment

1 reference

12 December 2020

Reduced responsiveness to epoetin at re-exposure after prolonged epoetin-free period in anemic hemodialysis patients with end-stage renal disease

1 reference

12 December 2020

Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients

1 reference

12 December 2020

Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD

1 reference

12 December 2020

Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients

1 reference

12 December 2020

https://api.crossref.org/works/10.1002%2F14651858.CD010590.PUB2

1 reference

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD010590.PUB2

2 references

Consolidated OpenCitations Corpus – April 2017

1595945

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25486075%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1595945

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25486075%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

PubMed publication ID

25486075

2 references

Consolidated OpenCitations Corpus – April 2017

1595945